Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data



Status:Completed
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:4/21/2016
Start Date:May 2004
End Date:April 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
We seek to improve the predictive accuracy of the nomogram to predict survival for patients
with castrate mets disease through the addition of pathological data, the results of
automated machine vision based image analysis of H&E stained tumor tissue developed at
Aureon Biosciences,and molecular biomarker studies (25 markers) determined by
immunohistochemistry on tissue microarrays prepared from paraffin-embedded tumor.


Inclusion Criteria:

Patients in the first retrospective study (Stage 1) must be part of the 409 patient strong
MSKCC cohort with progressive metastatic prostate cancer which was used for the generation
of the original nomogram.

For details please see original publication by Smaletz et al. Patients involved in the
second retrospective study (Stage 2) must be part of the 223 patients with a rising PSA
after surgery or radiation therapy who were treated on conjugate vaccine trials at MSKCC..

Exclusion Criteria:

For details of excluded patients on the clinical metastases castrate disease study, please
see original publication by Smaletz et al.4

• (MSKCC - add reference if publication available for rising PSA patients)
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials